Zobrazeno 1 - 10
of 76
pro vyhledávání: '"E. Tan Chiu"'
Autor:
Manuel Ruiz-Borrego, W. Lawler, A. Kellum, L. Carcas, K.D. Nahum, M. Wilkinson, K. Tkaczuk, Ron Bose, E. Ibrahim, D. Hunt, Sara A. Hurvitz, N. Erickson, M. Kozloff, R.H. Alvarez, M. Trudeau, I. Gore, D. Chan, K. Cheong, M. Coleman, F. Kass, A. Conlin, B. Choi, J. A. Di Palma, N. Iannotti, Adam Brufsky, Aurelio Castrellon, G. Marx, Debu Tripathy, M. Thirlwell, I. Vaziri, A.J. Chien, L. McCulloch, Gary Thomas, Vincent Hansen, A. Chan, Carlos H. Barcenas, D. Ellison, R. Dichmann, E. Reyes, J. A. Garcia Saenz, J. Seeger, N. Chan, S.D. Kendall, Barbara Pistilli, A. Litvak, R. Somer, D. Huang, D. Hufnagel, James L. Wade, Hope S. Rugo, Richard A. Bryce, E. Tan Chiu, Y. Manalo
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
instname
[Background]: Neratinib is an irreversible pan-HER tyrosine kinase inhibitor approved for extended adjuvant treatment in early-stage HER2-positive breast cancer based on the phase III ExteNET study. In that trial, in which no antidiarrheal prophylaxi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87edb03d992de035471fddfbe5b56293
http://hdl.handle.net/10261/237366
http://hdl.handle.net/10261/237366
Autor:
Gabriel N. Hortobagyi, David Chandiwana, G Volas-Redd, Mikhail Shtivelband, AA Dalal, Sara M. Tolaney, E Tan-Chiu, Cristina I. Truica
Publikováno v:
Cancer Research. 78:P1-13
Background: Improvement to and maintenance of the highest possible health-related quality of life (QoL), in addition to disease control, are key goals of treatment in patients with advanced breast cancer (ABC). Endocrine therapy is preferred as first
Autor:
E. Tan-Chiu, Reginald Ewesuedo, Mark D. Pegram, Alicia M. Vana, Charles Zacharchuk, Amy Freyman, Fiona Hilton
Publikováno v:
Annals of Oncology. 28:v74-v75
Autor:
John K. Forster, Harold J. Burstein, Stephen D. Rubin, Kimberly L. Blackwell, J. Maltzman, Lee S. Schwartzberg, S. Stein, E. Tan-Chiu, Mark D. Pegram, M. C. Arbushites
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 20(6)
Background: This phase II study evaluated the efficacy and safety of lapatinib in patients with human epidermal growth factor receptor 2 (HER2)-positive advanced or metastatic breast cancer that progressed during prior trastuzumab therapy. Patients a
Publikováno v:
Cancer. 91
This report updated previous findings, at the 15-year mark, of the National Surgical Breast and Bowel Project (NSAPB) Protocol B-06 with respect to the treatment of invasive breast carcinoma and the effects of pathologic features and the effects of s
Publikováno v:
Journal of the National Cancer Institute. 93(1)
The overall effect of prophylactic tamoxifen in women depends on the balance between the effects of the drug, which include preventing breast cancer and altering cardiovascular risk. In a recent clinical trial, postmenopausal estrogen-progestin thera
Autor:
E Bourbouloux, C Dansky Ullmann, Bohuslav Melichar, Huifeng Niu, Bin Zhang, Angela DeMichele, Claudia Schusterbauer, E Tan-Chiu, Antoine Adenis, Ely Benaim
Publikováno v:
Cancer Research. 73:PD5-5
Background: AAK, a key mitotic regulator, is frequently amplified/overexpressed across a spectrum of tumors, including BrC. AAK overexpression is associated with poor prognosis. MLN8237 is an oral selective AAK inhibitor under evaluation in pts with
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Journal of Clinical Oncology. 24:10591-10591
10591 Background: Phase III studies have demonstrated that the addition of T to chemo is associated with higher response rates (RR), improved time-to-progression (TTP) and improved overall survival in pts with metastatic HER2+ tumors. The greatest be
Autor:
D. M. Medina, M. Saleh, D. K. Washington, K. A. Meek, P. Cernohous, E. Tan-Chiu, Gary Gordon, A. M. V. Storniolo, Anne E. Hagey
Publikováno v:
Journal of Clinical Oncology. 23:724-724
724 Background: Therapy is limited for subjects with taxane-refractory metastatic breast cancer. ABT-751, an oral antimitotic agent that binds to the colchicine site of β-tubulin and prevents microtubule polymerization, has shown antitumor activity